Processa details Vidya deal progress and new leadership in stockholder letter
Processa Pharmaceuticals issued a November 5, 2026 letter to stockholders outlining its I&I pipeline strategy, financing runway, and executive additions following the Vidya Therapeutics acquisition.
SEC filing